Why the study?
What is the maximum tolerated dose of intravenous and intra-arterial N-acetylcysteine in adults with chronic kidney disease?
Population
28 adults with stage 3 or worse renal failure who had any endovascular procedure
Design
Cohort, non-randomized
Authors
Loading...
Supports further NAC investigation for cisplatin ototoxicity in children; leaves open clinical adoption pending larger trials.
What is the maximum tolerated dose of intravenous and intra-arterial N-acetylcysteine in adults with chronic kidney disease?
In adults with kidney impairment undergoing endovascular procedures, the maximum tolerated dose of N-acetylcysteine is 450 mg/kg for both intravenous and intra-arterial administration.
Dósa et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: